U.S. markets closed

Syndax Pharmaceuticals, Inc. (SNDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.23-0.34 (-1.74%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close19.57
Open19.38
Bid10.76 x 1100
Ask19.40 x 800
Day's Range18.55 - 19.48
52 Week Range13.02 - 27.85
Volume1,305,396
Avg. Volume872,978
Market Cap927.821M
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Buy These 2 Stocks Before They Jump Over 60%, Says Analyst
    TipRanks

    Buy These 2 Stocks Before They Jump Over 60%, Says Analyst

    We’re in interesting times, there’s no doubt about that. The COVID crisis is receding, the economic reopening is proceeding apace – but there are inflationary worries. The Biden Administration is committed to a heavy spending program, including generous extended unemployment benefits – which in some cases can exceed wages. As a result, the labor market is apparently stuck, running in low gear and prompting some concern that the recovery may not gain traction. Taking a macro view of the economic

  • Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial
    Benzinga

    Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial

    View more earnings on SNDXSee more from BenzingaClick here for options trades from BenzingaInflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis StudyMinerva Shares Surge As Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Dennis Podlesak Is The Independent Chairman of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) And Just Spent US$197k On Shares
    Simply Wall St.

    Dennis Podlesak Is The Independent Chairman of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) And Just Spent US$197k On Shares

    Potential Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders may wish to note that the Independent Chairman...